Post-ERCP pancreatitis: review of current preventive strategies.

Abstract

PURPOSE OF REVIEW:

This article reviews the most recent literature with significant findings pertaining to the prevention of postendoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.

RECENT FINDINGS:

Despite several promising reports of pharmacologic agents that have demonstrated the efficacy for prophylaxis against post-ERCP pancreatitis such as nonsteroidal anti-inflammatory drugs and secretin, there are currently no universally accepted agents for use in high-risk patients. The greatest reductions in the incidence of post-ERCP pancreatitis in high-risk patients have been demonstrated through advancements in endoscopic techniques such as pancreatic duct stenting and dye-free guidewire cannulation.

SUMMARY:

Pancreatitis requiring hospitalization is the most common complication of ERCP. Numerous pharmaceutical and procedure related interventions have been studied in attempts to prevent this complication; however, morbidity associated with ERCP remains significant. The most effective methods for preventing post-ERCP pancreatitis are careful patient selection and identification of risk factors prior to procedure.

• Authors: Matthew E Feurer, Douglas G Adler
• Journal: Current opinion in gastroenterology (Curr Opin Gastroenterol) Vol. 28 Issue 3 Pg. 280-6 (May 2012) ISSN: 1531-7056 [Electronic] United States
• PMID: 22450899 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal

Topics

• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Catheterization (methods)
• Cholangiopancreatography, Endoscopic Retrograde (adverse effects)
• Female
• Humans
• Male
• Pancreatic Ducts (surgery)
• Pancreatitis (etiology, prevention & control)
• Patient Selection
• Risk Factors
• Stents